Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

X-Linked Retinitis Pigmentosa Gene Therapy: Preclinical Aspects

8 Nov 2022

Abstract excerpt

The most common inherited eye disease is retinitis pigmentosa (RP). X-linked RP (XLRP) is one of the most severe types of RP, with a considerable disease burden. Patients with XLRP experience a decrease in their vision and become blind in their 4th decade of life, causing much morbidity after starting a rather normal life. Treatment of XLRP remains challenging, and current treatments are not effective enough in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ocular Disorders and Treatments
Share to Retinal Development and Disorders
Share to Retinal Diseases and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36346573
DOI: 10.1007/s40123-022-00602-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

X-Linked Retinitis Pigmentosa Gene Therapy: Preclinical AspectsPMID 36346573Read ↗

Pre-Clinical and Clinical Advances in Gene Therapy of X-Linked Retinitis Pigmentosa: Hope on the HorizonSemantic proximity Read ↗

Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa.Semantic proximity Read ↗

The New Era of Therapeutic Strategies for the Treatment of Retinitis Pigmentosa: From Pathomolecular Mechanisms to the Development of Cell-Based TherapiesSemantic proximity Read ↗

Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR.Semantic proximity Read ↗

Retinitis Pigmentosa: Progress in Molecular Pathology and Biotherapeutical StrategiesSemantic proximity Read ↗

RPGR-Related Retinopathy: Clinical Features, Molecular Genetics, and Gene Replacement Therapy.Semantic proximity Read ↗

Gene Therapy for Retinitis Pigmentosa: Current Challenges and New Progress.Semantic proximity Read ↗

Molecular Strategies for RPGR Gene TherapySemantic proximity Read ↗

RPGR and RP2: targets for the treatment of X-linked retinitis pigmentosa?Semantic proximity Read ↗

Retinitis pigmentosa and stem cell therapySemantic proximity Read ↗

Overcoming the Challenges to Clinical Development of X-Linked Retinitis Pigmentosa Therapies: Proceedings of an Expert Panel.Semantic proximity Read ↗

RPGR-associated retinopathy: clinical features, molecular genetics, animal models and therapeutic options.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.